Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML

Abstract | Dec 7, 2024

Author

Issa GC, et al.

Congress

American Society of Hematology Annual Meeting 2024

San Diego, California | Dec 7 – 10, 2024